

Teff
P9
P6
P10
P8
P7
Treg
CD45RA
CD25
Control (10μg/mL)
Teff
P9
P6
P10
P8
P7
Treg
CD45RA
CD25
TRAB/CTLA4 (10μg/mL)

FIG. 10-1



Donor 1
Treg (% with respect to CD4-positive cells)
10
8
6
4
2
0
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL
Donor 2
Treg (% with respect to CD4-positive cells)
10
8
6
4
2
0
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL

FIG. 10-2



Donor 1
Teff/Treg ratio
60
50
40
30
20
10
0
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL
Donor 2
Teff/Treg ratio
10
8
6
4
2
0
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL

FIG. 10-3



Teff
P11
P12
P13
Treg
CD45RA
FoxP3
Control (10μg/mL)
Teff
P11
P12
P13
Treg
CD45RA
FoxP3
TRAB/CTLA4(10μg/mL)

FIG. 11-1



Donor 1
Treg (% with respect to CD4-positive cells)
2
1.5
1
0.5
0
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL
Donor 2
Treg (% with respect to CD4-positive cells)
2
1.5
1
0.5
0
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL

FIG. 11-2



Donor 1
Teff/Treg ratio
1000000
100000
10000
1000
100
10
1
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL
Donor 2
Teff/Treg ratio
1000
100
10
1
Control
TRAB/CTLA4
0.1μg/mL
1μg/mL
10μg/mL

FIG. 11-3



4 days later
Teff
CD45RA
Fr.II (1)
Treg
CD25
Untreated
TRAB/LAG3 (10μg/ml)
6 days later

FIG. 13



4 days later
Treg (% with respect to CD4-positive cells)
3.5
3
2.5
2
1.5
1
0.5
0
Untreated
TRAB/LAG3 1μg/ml
TRAB/LAG3 10μg/ml
6 days later
Treg (% with respect to CD4-positive cells)
4
3.5
3
2.5
2
1.5
1
0.5
0
Untreated
TRAB/LAG3 1μg/ml
TRAB/LAG3 10μg/ml

FIG. 14



4 days later
Teff/Treg ratio
60
50
40
30
20
10
0
Untreated
TRAB/LAG3 1μg/ml
TRAB/LAG3 10μg/ml
6 days later
Teff/Treg ratio
30
25
20
15
10
5
0
Untreated
TRAB/LAG3 1μg/ml
TRAB/LAG3 10μg/ml

FIG. 15



Donor1
Teff
CD45RA
Fr.II
Treg
CD25
Untreated
TRAB/OX40 (10μg/ml)
Donor2
Teff
CD45RA
Fr.II
Treg
CD25
Untreated
TRAB/OX40 (10μg/ml)

FIG. 16



Donor1
Treg (% with respect to CD4-positive cells)
3
2.5
2
1.5
1
0.5
0
Untreated
TRAB/OX40 1μg/ml
TRAB/OX40 10μg/ml
Donor2
Treg (% with respect to CD4-positive cells)
2.5
2
1.5
1
0.5
0
Untreated
TRAB/OX40 1μg/ml
TRAB/OX40 10μg/ml

FIG. 17



Donor1
Teff/Treg ratio
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Untreated
TRAB/OX40 1μg/ml
TRAB/OX40 10μg/ml
Donor2
Teff/Treg ratio
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
Untreated
TRAB/OX40 1μg/ml
TRAB/OX40 10μg/ml

FIG. 18